Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

November 30, 2013

Conditions
Stomach NeoplasmsEsophageal Neoplasms
Interventions
DRUG

5-fluorouracil

DRUG

Oxaliplatin

DRUG

Leucovorin

Trial Locations (4)

27599

University of North Carolina, Chapel Hill

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

University of North Carolina

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt University

OTHER

NCT00515216 - Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors | Biotech Hunter | Biotech Hunter